Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance3 min read
MALVERN, Pa., March 21, 2022 (Globe NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a medical-phase biopharmaceutical company concentrated on discovering, creating, and commercializing gene therapies to cure blindness health conditions and developing a vaccine to help you save life from COVID-19, right now announced the appointment of Jessica Crespo, CPA, as Chief Accounting Officer and Senior Vice President, Finance. She assumed the purpose helpful March 18, 2022.
In this function, she will be liable for the improvement and execution of the Company’s economical technique, as perfectly as all company finance, accounting, and internal and exterior financial reporting capabilities. She will serve as a member of Ocugen’s management staff, reporting immediately to the CEO.
Ms. Crespo has more than 20 yrs of experience in accounting and money management. She has been with Ocugen considering the fact that 2019, formerly serving as Vice President, Corporate Controller and Treasurer. Prior to joining the Firm, she held economical management roles inside of Aerie Pharmaceuticals, Aralez Prescribed drugs and Cubist Prescription drugs where by she was dependable for economical and technological accounting and SEC reporting, which includes the implementation of new accounting criteria and the accounting and reporting of complex transactions. Prior to that, Ms. Crespo was a senior manager in Ernst & Young’s audit and assurance observe.
“Jess has been an crucial member of the Ocugen team for just about three years and we are delighted to realize her beneficial contributions with this expansion of her role. The Company has observed transformational growth over the earlier calendar year, as we function to progress the therapies in our pipeline towards regulatory acceptance. Jess’ information and experience will assistance us maintain that momentum,” reported Dr. Shankar Musunuri, Chairman of the Board, Chief Govt Officer, and Co-founder of Ocugen.
Ms. Crespo holds a Bachelor of Science in Accounting from Boston College or university and is a Accredited Community Accountant.
About Ocugen, Inc.
Ocugen, Inc. is a clinical-phase biopharmaceutical enterprise focused on getting, developing, and commercializing gene therapies to heal blindness health conditions and producing a vaccine to help you save lives from COVID-19. Our breakthrough modifier gene treatment platform has the potential to take care of multiple retinal ailments with a single drug — “one to many,” and our novel biologic products prospect aims to provide greater treatment to clients with underserved health conditions these kinds of as moist age-associated macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-establishing Bharat Biotech’s COVAXIN™ vaccine applicant for COVID-19 in the U.S. and Canadian markets. For a lot more data, please go to www.ocugen.com.
Cautionary Observe on Ahead-Wanting Statements
This press launch contains ahead-hunting statements inside the this means of The Non-public Securities Litigation Reform Act of 1995, which are subject matter to pitfalls and uncertainties. We could, in some cases, use terms these types of as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words and phrases that express uncertainty of long term events or results to identify these forward-searching statements. Such statements are subject to many vital elements, hazards and uncertainties that could induce real activities or success to differ materially from our recent anticipations. These and other pitfalls and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (“SEC”), including the danger factors described in the part entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press launch discuss only as of the day of this push release. Except as essential by legislation, we suppose no obligation to update forward-wanting statements contained in this press release whether as a result of new data, potential occasions or or else, following the date of this push launch.
Ocugen Speak to:
Head, Investor Relations & Communications